Evidence map›Paper›PMID 30400020›Full record

ArticleEndocrine-related cancer2018

Differential efatutazone's impact on mammary neoplasia dependent upon Brca1 dose.

Sahar J Alothman, Weisheng Wang, Shan Chao, Bhaskar V Kallakury, Edgar S Díaz-Cruz, Priscilla A Furth

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine-related cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sahar J AlothmanGraduate School of Arts and Science, Georgetown University, Washington, District of Columbia, USA.
Weisheng WangDepartment of Oncology, Georgetown University, Washington, District of Columbia, USA.
Shan ChaoGraduate School of Arts and Science, Georgetown University, Washington, District of Columbia, USA.
Bhaskar V KallakuryDepartment of Pathology, Georgetown University, Washington, District of Columbia, USA.
Edgar S Díaz-CruzDepartment of Oncology, Georgetown University, Washington, District of Columbia, USA.
Priscilla A FurthDepartment of Oncology, Georgetown University, Washington, District of Columbia, USA.

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI Louis M Weiner · 1990 to 2026
$71.5M
Progression and regression of mammary preneoplasiaR01CA112176 · NCI · GEORGETOWN UNIVERSITY · PI FURTH, PRISCILLA A. · 2005 to 2018
$3.1M
NCI NIH HHS P30 CA051008NCI NIH HHS R01 CA112176
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Tumor Suppressor ProteinsAnimalsAntineoplastic AgentsBRCA1 ProteinFemaleMammary Glands, AnimalMammary Neoplasms, ExperimentalMice, TransgenicPrecancerous ConditionsThiazolidinedionesAntineoplastic AgentsBRCA1 ProteinBrca1 protein, mouseefatutazoneThiazolidinedionesTumor Suppressor Proteins

Identifiers

PMID30400020
PMCPMC6944742

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.